Gastrointestinal functional bowel disorders: new therapies

被引：7

作者：

Chovet, M ^{[1
]}

机构：

[1] Parke Davis & Co, Inst Rech Jouveinal, F-94265 Fresnes, France

来源：

CURRENT OPINION IN CHEMICAL BIOLOGY | 2000年 / 4卷 / 04期

关键词：

D O I：

10.1016/S1367-5931(00)00100-9

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Present therapies for functional gastrointestinal disorders are symptomatic and mainly treat altered bowel habits. New therapies are focused on nerve-gut communication dysfunction: 5-HT3 antagonists and 5-HT4 agonists have demonstrated activity in clinical trials. Promising targets for upper gut dysmotility drugs are motilin and cholecystokinin A receptors. Tachykinins, calcitonin gene-related peptide or glutamate antagonists are the most relevant candidates for visceral pain.

引用

页码：428 / 432

页数：5

共 50 条

[1]

Bardhan KD, 2000, ALIMENT PHARM THERAP, V14, P23

[2] Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans [J].

Bouras, EP ;

Camilleri, M ;

Burton, DD ;

McKinzie, S .

GUT, 1999, 44 (05) :682-686

[3]

Bueno L, 1999, Can J Gastroenterol, V13 Suppl A, p42A

[4] Measurement of gastrointestinal motility in the GI laboratory [J].

Camilleri, M ;

Hasler, WL ;

Parkman, HP ;

Quigley, EMM ;

Soffer, E .

GASTROENTEROLOGY, 1998, 115 (03) :747-762

[5]

Camilleri M, 1999, ALIMENT PHARM THERAP, V13, P1149

[6]

Chieppa DM, 2000, EUR J CLIN INVEST, V30, P66

[7]

Choi MG, 1998, J PHARMACOL EXP THER, V285, P37

[8]

Clayton NM, 1999, NEUROGASTROENT MOTIL, V11, P207

[9] Role of glutamate receptors and nitric oxide in the rostral ventromedial medulla in visceral hyperalgesia [J].

Coutinho, SV ;

Urban, MO ;

Gebhart, GF .

PAIN, 1998, 78 (01) :59-69

[10]

Danysz W, 1998, PHARMACOL REV, V50, P597

← 1 2 3 4 5 →